Patents Examined by Tiffany Nicole Grooms
-
Patent number: 11643670Abstract: Described herein are methods of enhancing chromosomal homologous recombination to stimulate a loss of heterozygosity at a gene locus of interest in a living cell. These methods are driven by an enhancer component and a target-specific endonuclease component and proceed through a mechanism whereby: exogenous donor DNA that is homologous to the gene locus of interest is not introduced into the living cell; the desired allele of the gene locus of interest remains uncleaved; and the undesired allele is either uncleaved, cleaved at a single location, or cleaved at multiple locations. These methods have numerous applications, including the repair of risk alleles for disease prevention, the correction of heterozygous mutations in dividing cells, the design of cancer therapeutics, and the design of novel gene-drive strategies.Type: GrantFiled: January 29, 2019Date of Patent: May 9, 2023Assignee: Massachusetts Institute of TechnologyInventors: Guoping Feng, Jonathan Wilde, Tomomi Aida, Martin Wienisch, Qiangge Zhang
-
Patent number: 11634729Abstract: Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.Type: GrantFiled: May 17, 2019Date of Patent: April 25, 2023Assignee: BOLT THREADS, INC.Inventor: Thomas Stevens
-
Patent number: 11629350Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.Type: GrantFiled: February 3, 2021Date of Patent: April 18, 2023Assignee: SNIPR BIOME APSInventors: Virginia Martinez, Ruben Vazquez-Uribe, Adam Takos, Eric Van Der Helm, Jasper Clube
-
Patent number: 11624058Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.Type: GrantFiled: February 17, 2022Date of Patent: April 11, 2023Assignee: The General Hospital CorporationInventors: J. Keith Joung, Benjamin Kleinstiver
-
Patent number: 11613780Abstract: The disclosure describes the effects of transcription mediated from a promoter on the transcription mediated by divergently coupled supercoiling-sensitive promoter. Transcription initiated from a promoter inhibits transcription mediated by a specific supercoiling-sensitive promoter that is divergently coupled to the promoter. A gyrase inhibitor relieves this inhibition and substantially increases the transcription mediated by the specific supercoiling-sensitive promoter that is divergently coupled to another promoter. Accordingly, the invention pertains to a method for identifying a compound as a gyrase inhibitor or not a gyrase inhibitor based on differential expression of genes under the control of divergently coupled promoters in the presence of the compound. Another embodiment of the invention provides an assay for identifying one or more compounds from a library of compounds as a gyrase inhibitor.Type: GrantFiled: June 15, 2018Date of Patent: March 28, 2023Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Fenfei Leng, Xiaoduo Zhi, Samantha Dages, Kelley Dages
-
Patent number: 11578333Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.Type: GrantFiled: March 8, 2021Date of Patent: February 14, 2023Assignee: SNIPR Biome ApSInventors: Virginia Martinez, Ruben Vazquez-Uribe, Adam Takos, Eric Van Der Helm, Jasper Clube
-
Patent number: 11566236Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or inactivation of a transcriptional control sequence of a BCL11A gene in a cell by genome editing.Type: GrantFiled: February 5, 2019Date of Patent: January 31, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Tirtha Chakraborty, Michelle I-Ching Lin
-
Patent number: 11547716Abstract: The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use The invention relates infer alio to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.Type: GrantFiled: May 20, 2022Date of Patent: January 10, 2023Assignee: SNIPR Technologies LimitedInventor: Jasper Clube
-
Patent number: 11535843Abstract: The present disclosure provides methods of generating recombinant bacteriophage genomes. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a linear bacteriophage DNA genome, and isolating recombinant bacteriophages that express the heterologous nucleic acid sequence.Type: GrantFiled: May 31, 2018Date of Patent: December 27, 2022Assignee: The Charles Stark Draper Laboratory, Inc.Inventors: Connor McBrine, Jason Holder
-
Patent number: 11530272Abstract: RNA Control Devices and/or destabilizing elements (DE) can regulate the expression of Chimeric Antigen Receptors (CARs) in eukaryotic cells. More specifically, DEs, RNA Control Devices, and/or side-CARs can be used with small molecule ligands to regulate the expression of Chimeric Antigen Receptors. These DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs can be used in the treatment of disease.Type: GrantFiled: December 21, 2017Date of Patent: December 20, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11486010Abstract: The present disclosure relates to high-throughput detection of polyketides using genetically encoded biosensors.Type: GrantFiled: August 17, 2017Date of Patent: November 1, 2022Assignee: NORTH CAROLINA STATE UNIVERSITYInventors: Gavin J. Williams, Christian Kasey, Yiwei Li
-
Patent number: 11479793Abstract: The present invention discloses a system for targeted gene editing and related uses.Type: GrantFiled: July 15, 2016Date of Patent: October 25, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Shengkan Jin, Juan-Carlos Collantes
-
Patent number: 11479794Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: March 24, 2022Date of Patent: October 25, 2022Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11473108Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: March 24, 2022Date of Patent: October 18, 2022Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11434262Abstract: Provided herein are compositions, kits and methods useful in the construction of designer transcription activator-like effector (dTALE) polypeptides.Type: GrantFiled: October 26, 2016Date of Patent: September 6, 2022Assignee: President and Fellows of Harvard CollegeInventors: Feng Zhang, Le Cong, Sriram Kosuri, George M. Church
-
Patent number: 11414653Abstract: The present invention provides for an Aspergillus niger host cell comprising a gene of interest operatively linked to an ecm33 promoter of an ascomycete fungi, wherein the gene of interest is heterologous to the ecm33 promoter and/or to Aspergillus niger. In some embodiments, the gene of interest is a glycoside hydrolase enzyme. In some embodiments, the glycoside hydrolase enzyme is a glucosidase.Type: GrantFiled: September 6, 2018Date of Patent: August 16, 2022Assignees: National Technology & Engineering Solutions of Sandia, LLC, Battelle Memorial Institute, The Regents of the University of CaliforniaInventors: John M. Gladden, Saori Amaike Campen, Jinxiang Zhang, Jon K. Magnuson, Scott E. Baker, Blake A. Simmons
-
Patent number: 11401532Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: May 21, 2021Date of Patent: August 2, 2022Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11401522Abstract: Compositions and methods are provided for genome modification at a target site in the genome of a fungal cell. The methods and compositions are drawn to a guide polynucleotide/Cas endonuclease system for promoting modification of the DNA sequence at a target site in a fungal host cell genome.Type: GrantFiled: December 16, 2015Date of Patent: August 2, 2022Assignee: DANISCO US INCInventors: Benjamin S. Bower, Jimmy Chan, Jing Ge, Xiaogang Gu, Susan Mampusti Madrid, Danfeng Song, Mingmin Song, Michael Ward, Steven Sungin Kim
-
Patent number: 11390908Abstract: A C9orf72 DNA repeat expansion can be detected using a CRISPR Arrayed Repeat Detection System (CARDS). Based upon the compositions and methods supporting this platform primary cell cultures and/or blood cell smears can be tested under conventional clinical diagnostic laboratory conditions to diagnose genetically-based diseases having DNA repeat expansions, including but not limited to ALS. dCas9 constructs are also contemplated as having fluorescent proteins bound to any or all stem loop sequences, wherein detection of a plurality of dCas9 constructs having different colored fluorescent proteins can simultaneously detect at least six (6) different gene target loci.Type: GrantFiled: September 1, 2016Date of Patent: July 19, 2022Assignees: UNIVERSITY OF MASSACHUSETTS, UNIVERSITY OF CENTRAL FLORIDA FOUNDATION, INC.Inventors: Thoru Pederson, Hanhui Ma, Li-Chun Tu, Ardalan Naseri, Maximilaan Huisman, Shaojie Zhang
-
Patent number: 11390886Abstract: The present invention discloses a system for targeted gene editing and related uses.Type: GrantFiled: July 15, 2016Date of Patent: July 19, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Shengkan Jin, Juan-Carlos Collantes